|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/12/22 Iovance Biotherapeutics, Inc. 8-K:8,9 9/12/22 11:1.9M Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 28K 2: EX-99.1 Miscellaneous Exhibit HTML 8K 6: R1 Cover HTML 47K 9: XML IDEA XML File -- Filing Summary XML 12K 7: XML XBRL Instance -- tm2225637d1_8k_htm XML 15K 8: EXCEL IDEA Workbook of Financial Reports XLSX 8K 4: EX-101.LAB XBRL Labels -- iova-20220912_lab XML 96K 5: EX-101.PRE XBRL Presentations -- iova-20220912_pre XML 64K 3: EX-101.SCH XBRL Schema -- iova-20220912 XSD 12K 10: JSON XBRL Instance as JSON Data -- MetaLinks 25± 33K 11: ZIP XBRL Zipped Folder -- 0001104659-22-099284-xbrl Zip 16K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): i September 12, 2022
i IOVANCE BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
| i Delaware | ||
| (State of Incorporation) | ||
| i 001-36860 | i 75-3254381 | |
| Commission File Number | (I.R.S. Employer Identification No.) | |
| i 825 Industrial Road, i 4th Floor | ||
| i San Carlos, i California | i 94070 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
| ( i 650) i 260-7120 | ||
| (Registrant’s Telephone Number, Including Area Code) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| i ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| i ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| i ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
| i ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company i ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| i Common stock, par value $0.000041666 per share | i IOVA | i The Nasdaq Stock Market, LLC |
C:
| Item 8.01. | Other Events. |
As previously disclosed, on December 11, 2020, a purported stockholder derivative complaint (the “Derivative Action”) was filed by plaintiff Leo Shumacher against Iovance Biotherapeutics, Inc. (the “Company”), as nominal defendant, and certain of its current officers and directors, as defendants, in the Court of Chancery in the State of Delaware. On June 15, 2022, the parties agreed to a proposed settlement, set forth in a Stipulation of Compromise and Settlement (the “Stipulation”), which was submitted to the Court for approval. The Stipulation calls for the Company to adopt certain governance changes and for the Company to pay to plaintiff’s counsel $400,000 for certain legal fees and expenses.
On August 26, 2022, the Court entered a Scheduling Order setting a hearing to determine whether final approval will be given to the settlement. The hearing has been set for November 17, 2022 at 3:15 p.m. in the Leonard L. Williams Justice Center, 500 North King Street, Wilmington, Delaware 19801. As required by the Scheduling Order, the Company is filing the Notice of Pendency of Settlement of Action (the “Notice”) with this Current Report on Form 8-K, a copy of which is attached hereto as Exhibit 99.1.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Notice of Pendency of Settlement of Action, dated August 31, 2022. | |
| 104 | Cover Page Interactive Data File (embedded as Inline XBRL document) |
C:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: September 12, 2022 | IOVANCE BIOTHERAPEUTICS, INC. | |
| By: | /s/ Frederick G. Vogt | |
| Frederick G. Vogt, Interim CEO & General Counsel | ||
C:
C:
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 11/17/22 | None on these Dates | |||
| Filed on / For Period end: | 9/12/22 | |||
| 8/26/22 | ||||
| 6/15/22 | ||||
| 12/11/20 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/18/22 Iovance Biotherapeutics, Inc. 424B5 2:804K Toppan Merrill/FA |